Stage Ib2-IVa cervical cancer with Curative Radiation Therapy
Conditions
Interventions
Observation
UFT 300 or 400mg/Day
Sponsors
Gynecologic Oncology Trial and Investigation Consortium
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Pathologicaly confirmed cervical cancer(squamous cell carcinoma,adenosquamous carcinoma,adenocarcinoma) 2)FIGO: Ib2, IIa, IIb, IIIa, IIIb, IVa 3)Patients who have received CCRT within 3-12 weeks and determined to be PR or CR by CT or MRI. 4)Age: 20 years old-75 years old 5)Performance status: ECOG 0-2 6)Adequate organ functions. 7)Patients who have signed to an approved informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients who have received hysterectomy after radiation therapy. 2)Patients with uterine stump cancer. 3)Patients who have received NAC. 4)Patients with active infection. 5)Patients who have myocardial infarction or unstable angina or uncontrolled arrhythmia within 6 months. 6)Patients with severe complications (uncontrolled hypertension,uncontrolled diabetes,bleeding tendency,or rheumatology). 7)Patients who have had any other cancer within the past 5 years. 8)Patients with watery diarrhea. 9)Patients with psychiatric disease. 10)Patients who are pregnant or breast feeding. 11)Patients who have a history of hypersensitivity to UFT 12)Patients who are considered to be inappropriate for this study judged by the treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Suvival/Adverse event/Quality of Life/Cost effectiveness | — |
Countries
Japan
Contacts
Public ContactKeiichi Fujiwara
GOTIC002 Coordinating Office Saitama Medical University International Medical Center
Outcome results
None listed